Business
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif., May 11, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2026.
About this update from An2 Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":270,"url":"https://media.zenfs.com/en/business-wire.com/6b17db3a0524b08dc4e190dc7e827e16"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cdzpFRvVU0YQwfpBBBJ_qw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MA--/https://media.zenfs.com/en/business-wire.com/6b17db3a0524b08dc4e190dc7e827e16","width":480,"height":270},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ZI69v1YcRXV2ZXbrZu9kXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM2MA--/https://media.zenfs.com/en/business-wire.com/6b17db3a0524b08dc4e190dc7e827e16","width":480,"height":270}},"lazy":false},{"type":"text","content":"Oral epetraborole program in polycythemia vera advancing toward Phase 2","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung disease underway","length":93,"tagName":"p","attribs":{}},{"type":"text","content":"Data expected in 2Q/2026 from two studies of oral AN2-502998, under development for chronic Chagas disease: a Phase 1 first-in-human clinical trial and a non-human primate efficacy study","length":186,"tagName":"p","attribs":{}},{"type":"text","content":"Declared ENPP1 candidate for solid tumors advancing from early research into development","length":88,"tagName":"p","attribs":{}},{"type":"text","content":"MENLO PARK, Calif., May 11, 2026--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended March 31, 2026.","length":330,"tagName":"p"},{"type":"text","content":""This was an important quarter for AN2 as we announced an exciting new program in polycythemia vera that is planned to enter Phase 2 development in the third quarter of 2026. This program is supported by what we believe is a robust package of epetraborole preclinical and clinical enabling data. We commenced an investigator-initiated Phase 2 study in M. abscessus lung disease, completed dosing in a Phase 1 study for our Chagas disease program, and declared our ENPP1 candidate for the treatment of solid tumors, as well as strengthened our ba...